Horizon Oncology Center - Home

Clinical Trials

Clinical Trials

Here is a list of our currently enrolling clinical trials as of January 4, 2018

Breast Cancer

A Phase I, Multicenter, Open-Label, Multi-Part, Dose Escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and Her2 -Negative Breast Cancer (RAD1901-005)

A Phase Ib, Open-Label Study Evaluating The Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Trastuzumab Emtansine or with Trastuzumab and Pertuzumab (with and without Docetaxel) in Patients with Her2-Positive Breast Cancer and Atezolizumab with Doxorubicin and Cyclophosphamide in Her2-negative Breast Cancer (GO29831)


A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms (Constellation 0610-02)

Lung Cancer

A Phase Ib/2 Study of Viagenpumatucel-L (HS-110) in Combination with Multiple Treatment Regimens in Patients with Non-Small Cell Lung Cancer (The "Durga" Trial) (HS110-102)

A Multi-Center Open-Label Phase 1/2 Study of BGB324 in Combination with Erlotinib in Patients with Stage IIIb or Stage IV non-Small Cell Lung Cancer (BGBC004)

Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab with or without Trilaciclib (G1T28) in Patients with Untreated Extensive-Stage Small cell Lung cancer (G1T28-05)

SHERLOC: A Phase 2 Study of MM-121 in combination with Docetaxel versus Docetaxel Alone in Patients with Hergulin Positive, Locally Advanced or Metastatic Non-amall Cell Lung cancer (MM-121-01-02-09)


A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas (Constellation 1205-01)

A Phase 1 Dose escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (LAM-002A-NHL-CLN01)

Solid Tumors

A Phase 1b/2 Study of Ibrutinib combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Turmors (PCYC-1128-CA)

A Phase I Multicenter, Open Label Study of Enadenotucirev Combination with PD-1 Inhibitor in Subjects with Metastatic or Advanced Epithelial Tumors (ColoAd1-1003)

A Phase 1b/2, Open-label, Multicenter Study Assessing the Safety, tolerability, pharmacokinetics, and Preliminary Anti-Tumor Activity of MEDI14736 in Combination with AZD9150 or AZD5069 in Patients with Advanced solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination with MEDI4376 as Second Line Treatment in Patients with Recurrent and/or Metastaic Squamous Cell Carcinoma of the Head and Neck (D5660C00004)

A Phase 1b/2 Study of ARRY-382 in cobination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors (ARRAY-382-201)

A Phase I, Open label, Dose Escalation Study of the Safety and Pharmacokinetics of anti-PD-L1 monocolonal Antibody KN035 Administered in Subcutaneous Injection as a Single Agent to Subjects with Locally Advanced or Metastic Solid tumors (KN035-US-001)

A Phase 1 Study Evaluating the safety, Pharmacology, and Preliminary Activity of VT1021 in Patients with Advanced Solid Tumors (VT1021-01)

A Phase 1 Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients with Advanced Malignancies (BBI-DSP7888-101)